Back to results
US 2022/0175906 A1Published application
Zika virus rna vaccines
AssigneeModernaTX, Inc.
InventorsGiuseppe Ciaramella, Sunny Himansu
Life of this patent
Estimating the term…
Abstract
Provided herein, in some embodiments, are Zika virus RNA vaccines and methods of producing an antigen-specific immune response in a subject.
Claims21
A method comprising administering to a subject a messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) encoding a Japanese encephalitis virus (JEV) signal peptide fused to a Zika virus (ZIKV) prME protein comprising a sequence having at least 90% identity to SEQ ID NO:
- 7, wherein the mRNA is in a composition comprising a lipid nanoparticle.
2-38. (canceled)
A method comprising:
- administering to a subject a first dose and a second dose of a messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) encoding a Japanese encephalitis virus (JEV) signal peptide fused to a Zika virus (ZIKV) prME protein comprising a sequence having at least 95% identity to SEQ ID NO:
- 7, wherein the mRNA is in a composition comprising a lipid nanoparticle.
A method comprising:
- administering to a subject a first dose and a second dose of a messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) encoding a Japanese encephalitis virus (JEV) signal peptide fused to a Zika virus (ZIKV) prME protein comprising a sequence having at least 95% identity to SEQ ID NO:
- 7, wherein 100% of uracil nucleotides in the ORF of mRNA have a 1-methyl-pseudouridine modification, and wherein the mRNA is in a composition comprising a lipid nanoparticle, and wherein 20 μg-60 μg of the mRNA is administered to the subject.
Dependencies are inferred from the claim text.